TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06340490: A Phase I Clinical Trial of RJMty19 in Treatment of Subjects With Refractory Systemic Lupus Erythematosus

Sponsor: Guangdong Ruishun Biotech Co., Ltd · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 24 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$4,105,500

Rescue Site Savings

+$2,721,360

Unlock Full NCT06340490 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06340490 Rescue Dossier →